Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis
- PMID: 8782160
- DOI: 10.1016/0022-510x(95)00339-4
Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis
Abstract
Memantine, a clinically employed drug with N-methyl-D-aspartate (NMDA) receptor antagonistic effects, dose-dependently ameliorates neurological deficits in Lewis rat experimental autoimmune encephalomyelitis (EAE). Interestingly, this therapeutic effect was not due to dampened CNS inflammation, as assessed by immunohistochemical evaluation of spinal cord tissue. Furthermore, numbers of interferon gamma (IFN gamma) mRNA expressing cells were not decreased, as assessed by in situ hybridization. Systemic immunity in terms of numbers of IFN gamma secreting cells in response to immunodominant myelin basic protein (MBP) peptides ex vivo was not reduced, and non-toxic doses of memantine did not affect lymphocyte proliferation or IFN gamma secretion in vitro. Considering these findings, we hypothesize that effector mechanisms responsible for reversible neurological deficits in EAE may involve NMDA receptors, and this highlights neurons as targets during autoimmune neuroinflammation.
Similar articles
-
Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine.J Pharmacol Exp Ther. 2002 Jul;302(1):50-7. doi: 10.1124/jpet.302.1.50. J Pharmacol Exp Ther. 2002. PMID: 12065699
-
Memantine Modulates Oxidative Stress in the Rat Brain following Experimental Autoimmune Encephalomyelitis.Int J Mol Sci. 2021 Oct 20;22(21):11330. doi: 10.3390/ijms222111330. Int J Mol Sci. 2021. PMID: 34768760 Free PMC article.
-
Dose-dependent mechanisms relate to nasal tolerance induction and protection against experimental autoimmune encephalomyelitis in Lewis rats.Immunology. 1998 Jul;94(3):431-7. doi: 10.1046/j.1365-2567.1998.00526.x. Immunology. 1998. PMID: 9767428 Free PMC article.
-
Interferon gamma, interleukin 4 and transforming growth factor beta in experimental autoimmune encephalomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells.J Neurosci Res. 1995 Apr 1;40(5):579-90. doi: 10.1002/jnr.490400503. J Neurosci Res. 1995. PMID: 7602612
-
Spinal cord neuropathology in rat experimental autoimmune encephalomyelitis: modulation by oral administration of myelin basic protein.J Neuropathol Exp Neurol. 1997 Dec;56(12):1323-38. doi: 10.1097/00005072-199712000-00007. J Neuropathol Exp Neurol. 1997. PMID: 9413281
Cited by
-
Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis.Nat Rev Neurol. 2015 Dec;11(12):711-24. doi: 10.1038/nrneurol.2015.222. Epub 2015 Nov 20. Nat Rev Neurol. 2015. PMID: 26585978 Review.
-
Disruption of NMDA receptors in oligodendroglial lineage cells does not alter their susceptibility to experimental autoimmune encephalomyelitis or their normal development.J Neurosci. 2012 Jan 11;32(2):639-45. doi: 10.1523/JNEUROSCI.4073-11.2012. J Neurosci. 2012. PMID: 22238099 Free PMC article.
-
NMDA receptors are expressed in oligodendrocytes and activated in ischaemia.Nature. 2005 Dec 22;438(7071):1162-6. doi: 10.1038/nature04302. Nature. 2005. PMID: 16372011 Free PMC article.
-
Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis.J Neurosci. 2009 Mar 18;29(11):3442-52. doi: 10.1523/JNEUROSCI.5804-08.2009. J Neurosci. 2009. PMID: 19295150 Free PMC article.
-
Testing NMDA receptor block as a therapeutic strategy for reducing ischaemic damage to CNS white matter.Glia. 2008 Jan 15;56(2):233-40. doi: 10.1002/glia.20608. Glia. 2008. PMID: 18046734 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
